KAMADA LTD
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 21.7
- Dividend yield
- –
About Kamada
Pharmaceutical Preparations, SIC 2834
Kamada Ltd. is a biopharmaceutical company focused on the development, manufacturing, and commercialization of plasma-derived protein therapeutics. The company conducts business primarily through two distinct segments: Proprietary Products and Distribution. Its portfolio of commercial proprietary therapeutics includes KEDRAB for rabies exposure, GLASSIA for alpha-1 antitrypsin deficiency, CYTOGAM for cytomegalovirus, along with WINRHO SDF, HEPAGAM B, and VARIZIG. Through its distribution operations, the company markets third-party pharmaceuticals and biosimilar products. Its customer base includes healthcare systems, medical facilities, hospitals, physicians, and commercial partners worldwide.
The enterprise maintains its corporate headquarters in Rehovot, Israel, and operates a specialized manufacturing facility in Beit Kama, Israel. In addition, the company oversees three plasma collection centers located in the United States across Beaumont, Houston, and San Antonio, Texas. Kamada commercializes and supplies its therapeutic products within the United States market as well as across approximately thirty international export destinations globally.
Summary of the business section of Kamada's latest annual report, written by StockData.
Company profile
Company
- Legal name
- KAMADA LTD
- Headquarters
- Rehovot, L3
- Address
- 2 Holtzman St., Science Park 7670402
- Phone
- 97289406472
- Employees
- 393, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- KOST FORER GABBAY & KASIERER, Tel-Aviv, Israel
Stock & identifiers
- Ticker
- KMDA
- Exchange
- Nasdaq
- IPO date
- May 31, 2013
- Shares outstanding
- 58M, Dec 31, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1567529
- CUSIP
- M6240T109
- ISIN
- USM6240T1099
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Amir London | Chief Executive Officer | 61,875 |
| Shavit Beladev | VP Plasma Operations | 3,418 |
| Liron Reshef | VP Human Resources | – |
| Boris Gorelik | VP, BD and Strategic Programs | – |
| Yael Brenner | VP Quality | 11,266 |
| Eran Nir | VP, Operations | 10,398 |
| Chaime Orlev | Chief Financial Officer | 11,633 |
| Hanni Neheman | VP, Marketing & Sales | 3,417 |
| Nir Livneh | VP, General Counsel | 10,000 |
| Orit Pinchuk | VP Regulatory Affairs | 12,133 |
| Jon Knight | Vice President, US Commercial | – |
| Lilach Asher-Topilsky | Director | – |
| Ishay Davidi | Director | 22,084,287 |
| Uri Botzer | Director | – |
| Karnit Goldwasser | Director | – |
| Lilach Payorski | Director | – |
| David Tsur | Director | 407,929 |
| Benjamin Dekel | Director | – |
| Assaf Itshayek | Director | – |
| Leon Recanati | Director | 3,432,937 |
Employees
Headcount reported in annual reports
“had 393 employees based in Israel.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 31, 2013 | IPO | Initial public offering priced (424B4 prospectus) |
| May 28, 2013 | Listing | Registration of securities on an exchange (Form 8-A) |